PERSPECTA

News from every angle

← Back to headlines

Guggenheim Raises Price Target on Phathom Pharmaceuticals (PHAT)

Guggenheim has increased its price target for Phathom Pharmaceuticals (PHAT) from $20 to $25, explaining the reasons behind the upgrade.

1 Mar, 09:27 — 1 Mar, 09:27
PostShare

Sources

Showing 1 of 1 sources
YahooMostly Factual177d ago

Guggenheim Raises PT on Phathom Pharmaceuticals (PHAT) to $25 From $20, Here’s Why

Read full article →

Related Stories

Treasury Secretary Bessent's Bond Strategy Faces Scrutiny and Criticism

1h ago

Richtech Robotics Announces Stock Repurchase Program, Shares Rise

4h ago

Analyst Reactions to Dick's Sporting Goods Stock Decline Following Earnings

4h ago

Apollo, KKR, and IFM Investors Finalists in AB Ports Stake Sale

5h ago